Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

By N. Andreasen, Lennart Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, Bengt Winblad, Kaj Blennow. Archives of Neurology, 2001

609 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. (2003, methodology): “03-111 [1-42] and catalog No.”
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease (2013, positive): “For example, reduced CSF A β and elevated CSF tau are also associated with Lewy body dementia and vascular dementia (Andreasen et al., 2001; Blennow and Hampel, 2003).”
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study (2003, methodology): “A 42 was measured using a special high-sensitivity version of sandwich ELISA [INNOTEST -amyloid(1-42), Innogenetics, Ghent, Belgium] constructed to specifically measure A 42, as described previously.”
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline (2007, background): “The combination of Ab42 and total tau increases specificity and the negative predictive value (II): AD versus total group other dementias: 58–85% [113]; AD versus FTD: 85% [119]; AD versus DLB and VaD specificity 67% and 48%, respectively, with a negative predictive value of 95% (I) [130].”